AR129722A1 - Compuestos inhibidores de axl - Google Patents
Compuestos inhibidores de axlInfo
- Publication number
- AR129722A1 AR129722A1 ARP230101639A ARP230101639A AR129722A1 AR 129722 A1 AR129722 A1 AR 129722A1 AR P230101639 A ARP230101639 A AR P230101639A AR P230101639 A ARP230101639 A AR P230101639A AR 129722 A1 AR129722 A1 AR 129722A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituted
- cycloalkyl
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 22
- 229910052757 nitrogen Inorganic materials 0.000 abstract 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000005842 heteroatom Chemical group 0.000 abstract 15
- 229910052760 oxygen Inorganic materials 0.000 abstract 15
- 229910052717 sulfur Inorganic materials 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 229910003827 NRaRb Inorganic materials 0.000 abstract 13
- 125000005843 halogen group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 abstract 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical group C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 abstract 1
- IQTFEQLZLXDWTI-UHFFFAOYSA-N 1-azaspiro[4.6]undecane Chemical group C1CCNC21CCCCCC2 IQTFEQLZLXDWTI-UHFFFAOYSA-N 0.000 abstract 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 101000659525 Canis lupus familiaris Protein unc-119 homolog A Proteins 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 241001115402 Ebolavirus Species 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010072877 Intestinal fibrosis Diseases 0.000 abstract 1
- 241000700627 Monkeypox virus Species 0.000 abstract 1
- 101100222378 Mus musculus Cxcl10 gene Proteins 0.000 abstract 1
- 101100224522 Mus musculus Dppa3 gene Proteins 0.000 abstract 1
- 101100329418 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRG1 gene Proteins 0.000 abstract 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- 241000907316 Zika virus Species 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- QVAUSBVLMVBCPN-UHFFFAOYSA-N bicyclo[4.1.1]octane Chemical group C1C2CC1CCCC2 QVAUSBVLMVBCPN-UHFFFAOYSA-N 0.000 abstract 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical group C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical group C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004914 cyclooctane Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000005871 monkeypox Diseases 0.000 abstract 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical group C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- NWTSRIZEBKLUFM-UHFFFAOYSA-N spiro[4.6]undecane Chemical group C1CCCC21CCCCCC2 NWTSRIZEBKLUFM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263356421P | 2022-06-28 | 2022-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129722A1 true AR129722A1 (es) | 2024-09-18 |
Family
ID=89324379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101639A AR129722A1 (es) | 2022-06-28 | 2023-06-26 | Compuestos inhibidores de axl |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230416277A1 (https=) |
| EP (1) | EP4547246A2 (https=) |
| JP (2) | JP7785209B2 (https=) |
| KR (1) | KR20250027650A (https=) |
| CN (1) | CN119365453A (https=) |
| AR (1) | AR129722A1 (https=) |
| AU (1) | AU2023298047A1 (https=) |
| CA (1) | CA3260468A1 (https=) |
| CL (1) | CL2024004060A1 (https=) |
| IL (1) | IL317736A (https=) |
| MX (1) | MX2024015648A (https=) |
| TW (1) | TW202400603A (https=) |
| WO (1) | WO2024006726A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2025250276A1 (en) * | 2024-05-28 | 2025-12-04 | Taiho Pharmaceutical Co., Ltd. | Methods for treatment of non-small cell lung cancers |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| PT1906965E (pt) * | 2005-06-22 | 2015-09-03 | Chemocentryx Inc | Compostos de azaindazol e métodos de utilização |
| CA2710046C (en) | 2006-12-29 | 2016-02-09 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| EP3444251B1 (en) * | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN112243439A (zh) * | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
| CA3108732A1 (en) * | 2018-08-28 | 2020-03-05 | Merck Patent Gmbh | Fused imidazopyridines as reversible inhibitors of bruton's tyrosine kinase (btk) |
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
| TWI848141B (zh) | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| US12459958B2 (en) * | 2019-07-17 | 2025-11-04 | Beone Medicines I Gmbh | Tricyclic compounds as HPK1 inhibitor and the use thereof |
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| WO2021239133A1 (zh) | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
| WO2022184152A1 (zh) | 2021-03-03 | 2022-09-09 | 劲方医药科技(上海)有限公司 | 稠环取代的六元杂环化合物及其制法和用途 |
| EP4341261A1 (en) * | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| CN115504967A (zh) | 2021-06-23 | 2022-12-23 | 南京正大天晴制药有限公司 | 作为axl抑制剂的1,2,4-三唑化合物 |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
-
2023
- 2023-06-26 AR ARP230101639A patent/AR129722A1/es unknown
- 2023-06-27 US US18/341,844 patent/US20230416277A1/en active Pending
- 2023-06-27 AU AU2023298047A patent/AU2023298047A1/en active Pending
- 2023-06-27 CN CN202380047386.9A patent/CN119365453A/zh active Pending
- 2023-06-27 CA CA3260468A patent/CA3260468A1/en active Pending
- 2023-06-27 WO PCT/US2023/069124 patent/WO2024006726A2/en not_active Ceased
- 2023-06-27 JP JP2024574683A patent/JP7785209B2/ja active Active
- 2023-06-27 EP EP23832486.7A patent/EP4547246A2/en active Pending
- 2023-06-27 TW TW112123754A patent/TW202400603A/zh unknown
- 2023-06-27 KR KR1020247041573A patent/KR20250027650A/ko active Pending
- 2023-06-27 IL IL317736A patent/IL317736A/en unknown
-
2024
- 2024-08-14 US US18/805,490 patent/US12195482B1/en active Active
- 2024-12-16 MX MX2024015648A patent/MX2024015648A/es unknown
- 2024-12-27 CL CL2024004060A patent/CL2024004060A1/es unknown
-
2025
- 2025-12-02 JP JP2025216661A patent/JP2026041858A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416277A1 (en) | 2023-12-28 |
| WO2024006726A3 (en) | 2024-04-25 |
| KR20250027650A (ko) | 2025-02-27 |
| WO2024006726A2 (en) | 2024-01-04 |
| JP2026041858A (ja) | 2026-03-10 |
| CL2024004060A1 (es) | 2025-05-16 |
| US12195482B1 (en) | 2025-01-14 |
| TW202400603A (zh) | 2024-01-01 |
| CA3260468A1 (en) | 2024-01-04 |
| MX2024015648A (es) | 2025-02-10 |
| EP4547246A2 (en) | 2025-05-07 |
| AU2023298047A1 (en) | 2025-01-09 |
| JP7785209B2 (ja) | 2025-12-12 |
| JP2025525364A (ja) | 2025-08-05 |
| IL317736A (en) | 2025-02-01 |
| US20240425526A1 (en) | 2024-12-26 |
| CN119365453A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129722A1 (es) | Compuestos inhibidores de axl | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| PE20252237A1 (es) | Inhibidores macrociclicos de kras y metodos de uso | |
| AR057716A1 (es) | Inhibidores de las serina proteasas y composiciones farmaceuticas | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR043859A1 (es) | Inhibidores de serina proteasas, particularmente de la proteasa ns3-ns4a del hcv | |
| PE20260006A1 (es) | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos | |
| RU2008126245A (ru) | Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| AR119069A1 (es) | Compuestos para el tratamiento de trastornos dependientes de quinasas | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| PE20251389A1 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| AR119149A1 (es) | Derivados de isoquinolina como moduladores de la progranulina | |
| AR127355A1 (es) | Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos | |
| AR123700A1 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR122407A1 (es) | Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23 | |
| AR123701A1 (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| PE20260297A1 (es) | Compuestos anti-vih | |
| AR119030A1 (es) | 5H-TIOCROMENO[4,3-b]PIRIDIN-2-OXO-3-CARBOXILATOS O SUS DIOXO O TRIOXO DERIVADOS Y SU USO EN EL TRATAMIENTO O PROFILAXIS DE LA HEPATITIS B |